Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pharming Group N.V. (PHGUF)
:PHGUF
Holding PHGUF?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
<0.01Last Year’s EPS
>-0.01Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 25, 2018
|% Change Since: 4.40%
|Next Earnings Date:Jul 26, 2018
Earnings Call Sentiment|Neutral
The earnings call highlights strong performance and growth in key products like RUCONEST and Joenja, improved financial metrics, and promising pipeline developments. However, this is balanced by a net loss, increased expenses, and market challenges for Joenja outside the U.S.Company Guidance
During the Q3 2024 earnings call for PHARM.AS, the company provided detailed guidance highlighting significant growth metrics and future plans. RUCONEST continued to be a cornerstone, generating nearly $64 million in the third quarter and $173 million over the first nine months of 2023, marking substantial cash flow for the company. Joenja, the first FDA-approved treatment for APDS, achieved $32 million in sales year-to-date, reflecting robust growth. The company is actively expanding its market reach, with regulatory actions in the U.S., U.K., Israel, and ongoing reviews in Canada and Australia. Notably, PHARM.AS began a Phase II trial for leniolisib in a new indication, targeting a broader patient population with primary immune deficiencies, which is approximately five times larger than the APDS market. The financial outlook remains positive, with anticipated revenues landing around the midpoint of the $82 million to $95 million guidance range, driven by Joenja's growth and sustained demand for RUCONEST. The company is also keenly focused on acquiring clinical-stage opportunities to bolster its portfolio in rare diseases.Strong RUCONEST Performance
RUCONEST continues to grow with $64 million in the third quarter and $173 million in the first 9 months of 2023, showing strong market presence and patient uptake.
Joenja Revenue Growth
Joenja, the FDA-approved treatment for APDS, achieved $32 million in sales in the first 9 months of the year, demonstrating significant growth.
Financial Improvement
Operating profit increased to $4.1 million from $1.9 million last year, driven by increased gross profit despite higher operating expenses.
Pipeline Expansion
Initiated Phase II trials for leniolisib in primary immune deficiencies, indicating a commitment to expanding treatment offerings.
Improved Cash Flow
Cash and cash equivalents increased to $173.3 million from $161.8 million, driven by positive cash flows from operations.
---
PHGUF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PHGUF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 24, 2024 | $0.91 | $0.81 | -10.99% |
| Aug 01, 2024 | $0.87 | $0.80 | -8.05% |
| May 08, 2024 | $0.96 | $0.94 | -2.08% |
| Mar 14, 2024 | $1.18 | $1.10 | -6.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pharming Group N.V. (PHGUF) report earnings?
Pharming Group N.V. (PHGUF) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Pharming Group N.V. (PHGUF) earnings time?
Pharming Group N.V. (PHGUF) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PHGUF EPS forecast?
PHGUF EPS forecast for the fiscal quarter 2024 (Q4) is <0.01.
---